89bio

89bio, Inc. Announces Agreement to be Acquired by Roche

September 18, 2025 01:02 ET  | Source: 89bio, Inc. – 89bio stockholders to receive up to $20.50 per share in…

3 months ago

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most…

3 months ago